Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Peter Šišovský; Nikola Gejgusova; Tomáš Fazekaš; Ján Klimas; Girish Dhall

doi:10.1080/14796694.2026.2621651

January 29, 2026Future Oncology

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to enhance molecular preselection for pediatric patients receiving tyrosine kinase inhibitors for solid tumors.
Reviewed current molecular preselection criteria for pediatric tumors
Analyzed molecular factors influencing treatment response
Proposed improvements based on findings
Current criteria identified as insufficient for optimizing treatment
Highlighted need for better molecular understanding to guide therapy
Encouraged tailored approaches to improve outcomes

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Research examines tumor molecular factors affecting efficacy of tyrosine kinase inhibitors in pediatric patients, suggesting improvements for pre-selection criteria.

Abstract

Molecular background of tumors should be taken into account when using TKIs. The current molecular pre-selection criteria are insufficient and need to be improved.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Šišovský et al. (2026) studied this question.

synapsesocial.com/papers/6980fbbec1c9540dea80d7e9 https://doi.org/10.1080/14796694.2026.2621651

View at Publisher

Ask AI

Bookmark

Share

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading